BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2019 8:35:15 AM | Browse: 134 | Download: 128
Publication Name World Journal of Diabetes
Manuscript ID 46649
Country/Territory United States
2019-02-21 00:21
Peer-Review Started
2019-02-22 07:05
To Make the First Decision
2019-05-09 00:29
Return for Revision
2019-05-09 02:08
2019-05-15 01:50
Second Decision
2019-05-22 09:22
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-05-23 13:14
Articles in Press
2019-05-23 13:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-06-12 08:59
Publish the Manuscript Online
2019-06-14 08:35
ISSN 1948-9358 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology and Metabolism
Manuscript Type Minireviews
Article Title Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications
Manuscript Source Invited Manuscript
All Author List Ravi Kant, Kashif M Munir, Arshpreet Kaur and Vipin Verma
Author(s) ORCID Number
Ravi Kant http://orcid.org/0000-0002-9599-8082
Kashif M Munir http://orcid.org/0000-0002-1075-1284
Arshpreet Kaur http://orcid.org/0000-0002-7266-9358
Vipin Verma http://orcid.org/0000-0001-5370-3146
Funding Agency and Grant Number
Corresponding author Ravi Kant, MD, Associate Professor, Division of Endocrinology, Diabetes and Nutrition, Medical University of South Carolina/Anmed Campus, 2000 E Greenville St., Suite # 3100, Anderson, SC29621, United States. Kant.ravi.md@gmail.com
Keywords Newer antidiabetic medications; Glucagon-like peptide-1 receptor agonist; Sodium-glucose cotransporter-2 inhibitors; Type 2 diabetes mellitus; Macrovascular complications; Cardiovascular outcome trials; Major cardiovascular events; Heart failure; Prevention of heart disease
Core Tip Multiple cardiovascular (CV) outcome trials performed mainly to meet regulatory requirements by United States Food and Drug Administration have provided very important findings on CV safety and efficacy of newer anti-diabetic drugs. All drugs in glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2)-inhibitor classes have shown to be CV safe with heterogeneous results on CV efficacy. Abundance of data and heterogeneity in CV outcome trials results can make it difficult for clinicians to stay updated with all the recent evidence. The scope of this comprehensive review will focus on all major CV outcome studies evaluating CV safety and efficacy of GLP-1 RAs and SGLT-2 inhibitors.
Publish Date 2019-06-14 08:35
Citation Kant R, Munir KM, Kaur A, Verma V. Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. World J Diabetes 10(6): 324-332
Url https://www.wjgnet.com/1948-9358/full/v10/i6/324.htm
DOI https://dx.doi.org/10.4239/wjd.v10.i6.324
Full Article (PDF) WJD-10-324.pdf
Full Article (Word) WJD-10-324.docx
Manuscript File 46649-Review.docx
Answering Reviewers 46649-Answering reviewers.pdf
Audio Core Tip 46649-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 46649-Conflict-of-interest statement.pdf
Copyright License Agreement 46649-Copyright license agreement.pdf
Peer-review Report 46649-Peer-review(s).pdf
Scientific Misconduct Check 46649-Scientific misconduct check.pdf
Scientific Editor Work List 46649-Scientific editor work list.pdf